Five things for pharma marketers to know: Friday, November 17, 2017

Share this content:


1. The FDA approved Genentech's hemophilia A treatment emicizumab, known as Hemlibra. The drug has a boxed warning due to the risk of blood clots. (Endpoints News)

2. Former Insys Therapeutics CEO John Kapoor has pleaded not guilty to charges that he lead a conspiracy to bribe doctors to overprescribe fentanyl. (Forbes)

3. Eli Lilly settled a lawsuit in June alleging that the drugmaker provided free nursing services to persuade doctors to prescribe insulins Humalog and Humulin as well as osteoporosis drug Forteo. The suit noted that Eli Lilly worked with Healthstar Communications and VMS Biomarketing to provide those services. (Fierce Pharma)

4. A federal jury ruled that Endo International was not responsible for a heart attack suffered by a man using the company's testosterone-replacement drug Testim. Endo faces 1,290 state and federal lawsuits related to Testim. (Reuters)

5. The Trump Administration has presented changes to Medicare drug plans that would place limits on opioid prescriptions and lower the cost of drugs. (Reuters)

Share this content:
Scroll down to see the next article